Breast Cancer

Novel antibody-drug conjugates introduce promising options for the management of patients with HER2-positive breast cancer; however, management of drug-related toxicities and optimal sequencing of HER2-targeted therapies remains an ongoing challenge.

Ruth O’Regan, MD, discusses emerging CDK4/6 inhibitor combinations in breast cancer.

Ado-trastuzumab emtansine demonstrated a consistent invasive disease-free survival benefit versus trastuzumab in patients with HER2-positive breast cancer across all biomarker subgroups evaluated in the pivotal phase 3 KATHERINE trial.

Heather ​S. Han, MD, discusses the importance of pathologic complete response in breast cancer.

Sara A. Hurvitz, MD, discusses unmet needs within the field of HER2-positive breast cancer.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses immunotherapy, PARP inhibitors, and antibody-drug conjugates, which have become pillars of treatment in triple-negative breast cancer.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses ​treatment considerations in triple-negative breast cancer.

Hung Khong, MD, discusses the potential benefit of combining immunotherapy with endocrine therapy in estrogen receptor–positive, HER2-negative breast cancer.

Debu Tripathy, MD, discusses fam-trastuzumab deruxtecan-nxki versus ado-trastuzumab emtansine in HER2-expressing breast cancers.

Kamran A. Ahmed, MD, discusses the role of multidisciplinary care in breast cancer–related brain metastases.

CDK4/6 inhibitors alone and/or in combination with HER2-directed therapies have been shown to elicit encouraging response rates and inhibit the growth of the cancer cells in HER2-positive breast cancer.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses using biomarkers to determine the benefits of immunotherapy and chemotherapy in triple-negative breast cancer.

Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, discusses the risk of late recurrence in early breast cancer, current approaches to extended adjuvant endocrine therapy, and ongoing research evaluating assays aimed at capturing both the risk of late recurrence and benefit from extended endocrine therapy.

Atezolizumab in combination with paclitaxel did not demonstrate a statistically significant improvement in progression-free survival as a first-line treatment for patients with PD-L1–positive triple-negative breast cancer, failing to meet the primary end point of the IMpassion131 trial.

Kamran A. Ahmed, MD, discusses remaining questions with the use of tucatinib in breast cancer–related brain metastases.

A panel of experts in breast cancer discuss the emergence of alpelisib, review data from the BYLieve trial, discuss the role of everolimus, and review the emergence of oral taxanes.

Hatem Soliman, MD, discusses the rationale for using immunotherapy in triple-negative breast cancer.

Although strategies for treating brain metastases in patients with advanced breast cancer are showing signs of efficacy, new approaches are needed to prevent high-risk, HER2-positive early disease from spreading to the central nervous system.

Joyce A. O'Shaughnessy, MD, discusses the importance of research regarding the application of DNA repair deficiency in breast cancer, even though it's still in early stages.

One of the most important tasks that oncology nurses face is ensuring that patients are taking their medications consistently and correctly, and that adverse events are properly managed—specifically in those patients with breast cancer.

Ruth O’Regan, MD, discusses biomarkers of response to CDK4/6 inhibitors in breast cancer.

Debu Tripathy, MD, discusses genomically guided therapy in breast cancer.

Hung Khong, MD, discusses antiestrogen and immunotherapy combinations in ER-positive, HER2-negative breast cancer.

The FDA has accepted 2 supplemental biologics applications for pembrolizumab in patients with triple-negative breast cancer; these are the first US applications for the anti–PD-1 therapy in breast cancer.

The FDA has approved the new VENTANA HER2 Dual ISH DNA Probe Cocktail test for use as a companion diagnostic for trastuzumab and to detect HER2 mutations in patients with breast cancer.

Jennifer Litton, MD, discusses findings from the phase 3 EMBRACA trial on talazoparib in patients with advanced BRCA1/2-positive breast cancer.